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Abstract
A key question in understanding AD is whether extracellular Ab deposition of parenchymal amyloid plaques or
intraneuronal Ab accumulation initiates the AD process. Amyloid precursor protein (APP) is endocytosed from the cell
surface into endosomes where it is cleaved to produce soluble Ab which is then released into the brain interstitial fluid.
Intraneuronal Ab accumulation is hypothesized to predominate from the neuronal uptake of this soluble extracellular Ab
rather than from ER/Golgi processing of APP. We demonstrate that substitution of the two adjacent histidine residues of
Ab40 results in a significant decrease in its binding with PC12 cells and mouse cortical/hippocampal neurons. These
substitutions also result in a dramatic enhancement of both thioflavin-T positive fibril formation and binding to preformed
Ab fibrils while maintaining its plaque-binding ability in AD transgenic mice. Hence, alteration of the histidine domain of Ab
prevented neuronal binding and drove Ab to enhanced fibril formation and subsequent amyloid plaque deposition - a
potential mechanism for removing toxic species of Ab. Substitution or even masking of these Ab histidine residues might
provide a new therapeutic direction for minimizing neuronal uptake and subsequent neuronal degeneration and
maximizing targeting to amyloid plaques.
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Introduction
Extracellular accumulation of Ab in different soluble mono-
meric or polymeric forms and its extracellular aggregation leading
to plaque formation within the hippocampus and cortex is one of
the hallmark pathologies of AD [1]. It has been estimated that
70% of the interstitial fluid Ab arises from endocytosis-associated
mechanisms in neurons which is dependent upon synaptic activity
rather than from ER/Golgi processing of APP [2]. During AD
pathogenesis, the Ab can exist as soluble Ab monomers or
oligomers or aggregate into insoluble species, including protofibrils
and fibrils, which ultimately result in amyloid plaque formation.
Intraneuronal accumulation of Ab may arise from the uptake of
this soluble pool of Ab into neurons that disrupts its normal
function ultimately leading to apoptosis [3] and oxidative injury
[4] that seems to occur even before the formation of senile plaques
and neurofibrillary tangles. Wirths et al. [5] have recently
reviewed biochemical, neuropathological, and genetic information
that indicates Ab accumulation in neurons precedes its formation
as amyloid plaques in the extracellular space and have
hypothesized that intraneuronal Ab accumulation is the first step
of a fatal cascade of events leading to neurodegeneration in AD.
Numerous reports have supported this viewpoint (also reviewed by
Echeverria and Cvello [6], Tseng et al. [7], and Gouras et al. [8]),
and include Mochizuki et al. [9], who have reported that cells that
were immunoreactive for Ab42 are localized around amyloid
plaques in sporadic AD cases and Gouras [10] who demonstrated
intraneuronal AB staining was most evident in brain regions that
show the first signs of plaque accumulation, such as entorhinal
cortex and hippocampus. A good example of the neuropatholog-
ical consequences of intraneuronal Ab can be found in presenilin
mutation bearing AD transgenic mice which show extensive
intraneuronal Ab accumulation and subsequent neuronal death
without any amyloid plaque formation in the brain [11]. Ab-
burdened neurons undergo lysis and the aggregated Ab may be
the nidus for extracellular plaque formation as it is released into
the extracellular space [12].
Recently, Kandimalla et al. [13] reported that fluorescein-
labeled Ab40 was selectively accumulated in a subpopulation of
cortical and hippocampal neurons and in PC12 cells via non-
saturable, energy independent, and non-endocytotic pathways
through a mechanism that most likely results in biophysical
interaction with the neuronal membrane. This finding challenges
the conventional belief that Ab proteins are internalized via
receptor-mediated endocytosis. A large portion of the internalized
Ab40 was located outside of the endosomal or lysosomal
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accumulate in the neuroplasm without degradation where it could
subsequently aggregate to form fibrils, which ultimately results in
the degeneration of the neuron. Understanding the mechanism of
neuronal uptake of Ab is an important direction to take as it might
lead to potential therapeutic targets that would minimize this
uptake and the subsequent neurodegeneration that leads to the
pathogenesis of AD.
In this study, we hypothesize that a specific domain of Ab
protein provides a structural basis for its neuronal binding, which
ultimately triggers its internalization. It has been suggested that
Ab-microglial interactions occur through membrane-associated
heparin sulfate interactions with the HHQK domain of Ab [14].
This same cluster of basic amino acids is also known as a domain
with high-binding affinity for heparin sulfate. These authors have
suggested that HHQK-like agents may offer a specific therapy to
block plaque-induced microgliosis. Epitope mapping studies have
revealed that positively charged amino acid clusters with common
epitopes of Ab (HHQKL) and APO-E (LRKRL) are regions that
are known to be heparin-binding domains [15]. These authors
have substituted Ab residues with glycine (GGQGL) and found
that they failed to compete with the cellular uptake of APO-E
enriched bVLDL. They suggest that these observations indicate
that Ab and APO-E are taken up into cells by a common
pathway involving heparin sulfate proteoglycans. Diaz et al. [16]
have observed that small peptides of Ab that have replacements
of histidine 13 and 14 by alanine or lysine block the Ab ion
channel activity. Tickler et al. [17] demonstrated that methyla-
tion in the imidazole side chains of all three histidine residues on
Ab resulted in a four-fold increase in H2O2 generation. Despite
the higher levels of H2O2, the modified peptides were not
neurotoxic. These modifications both altered Cu binding and
inhibited peptide/cell surface membrane interaction. In similar
studies by the same group, Smith et al. [18] determined that
copper-mediated Ab toxicity was associated with an intermolec-
ular bridge involving histidines 6, 13, and 14 of Ab.M e t h y l a t i o n
of these histidine residues was shown to be non-toxic in cell
culture systems, because these chemical modifications inhibited
the interaction between the peptide and the cell surface
membrane. Interestingly, three amino acid differences exist in a
comparison of human Ab peptide with the rodent Ab peptide
(Arg-5RGly; Tyr-10RPhe and His-13RArg). Despite these
three amino acid substitutions, no difference was observed in
the ability of either rodent or human peptides to form fibrils in
aqueous buffer [19-21], yet rats and mice do not innately develop
age-associated amyloid pathology [22]. Replacement of the His-
13 for Arg in rodent Ab disrupts the metal coordination site
which results in the rodent peptide having less ability to zinc-
induced aggregation in vitro [23-25]. In addition, the rodent form
of Ab that has His13 mutated to an Arg has been shown to be
non-toxic [26]. Indeed platinum-based compounds that target
histidine residues on Ab inhibit Ab toxicity [27]. All of these
studies point to a critical role of histidine residues at positions 13
and 14 on Ab protein. As a result, we decided to evaluate the
effects of H13,14 substitution of Ab40 on its ability to affect
neuronal binding in a culture model of differentiated PC12 cells
and in cortical and hippocampal neurons in WT mouse brain
slices. These in vitro systems have been well characterized and
used by numerous investigators as models to study neuronal
physiology [28-31]. Because of the well recognized involvement
of Ab in forming fibrils and amyloid plaques, we also evaluated
the effects of H13,14 substitution of Ab40 on its subsequent
ability to form fibrils, bind to Ab fibrils, and label amyloid
plaques.
Methods
2.1 Peptides
Human Ab1-40, with the sequence DAEFRHDSGYEVHH-
QKLVFFAEDVGSNKGAIIGLMVGGVV, Ab1-40 H13G with
the sequence DAEFRHDSGYEVGHQKLVFFAEDVGSNKG-
AIIGLMVGGVV, Ab1-40 H13,14G with sequence DAEFRH-
DSGYEVGGQKLVFFAEDVGSNKGAIIGLMVGGVV, Ab1-
40 H13R with sequence DAEFRHDSGYEVRHQKLVFFAE-
DVGSNKGAIIGLMVGGVV, and Ab1-40 R5G, Y10F, H13R
(rodent Ab1-40) with sequence DAEFGHDSGFEVRHQKLV-
FFAEDVGSNKGAIIGLMVGGVV were synthesized with or
without Ahx (Fmoc-6-aminohexanoic acid) attached to the N-
terminal on a CEM Liberty (Mathews, NC) peptide synthesizer
using HBTU activation and the manufacturer’s suggested synthesis
protocols. Thestarting resinwas Val-NovaSynTGA (Novabiochem
EMD Biosciences, San Diego, CA). For fluoresceinated peptides,
aftercompletionofthesynthesisandfinalFmocdeprotection,NHS-
fluorescein, [5-(and 6)-carboxyfluorescein, succinimidyl ester]
(Pierce) was added to the N-terminal Ahx residue by dissolving
fluorescein in 2 ml of DMSO/8 ml DMF and reacting the
fluorescein solution with the peptide-resin, which had been washed
previously with DIEA/DCM. The coupling of fluorescein was
allowed to proceed overnight at RT. The peptides were then
cleaved from the resin support using 5% crystalline phenol, 5%
water, 2.5% triisopropylsilane, and 87.5% TFA for two hours at
RT. The peptide was purified by reverse-phase HPLC on a Jupiter
C18 column (250 mm621.2 mm, Phenomenex Corp) using a
gradientsystem of 0.1% aqueous TFAcontaining 80%acetonitrile/
water/0.1% TFA. The calculated mass weight was 4329 amu for
Ab1-40; 4249 amu for Ab1-40 H13G; 4169 amu for Ab1-40
H13,14G; 4348 amu for Ab1-40 H13R; and 4233 amu for Ab1-40
R5G, Y10F, H13R as confirmed by electrospray ionization mass
spectrometry (Thermoelectron Surveyor MSQ).
2.2 Cell Culture
PC12 cells were maintained in DMEM supplemented with 10
mM HEPES (pH 7.4), 10% fetal bovine serum, 4 mM L-
glutamine, penicillin (200 U/mL) and streptomycin (200 mg/mL)
in 5% CO2 at 37uC. Cells were plated at 1.5610
4 cells per well in
uncoated 6-well Falcon plates (Becton Dickinson Labware,
Franklin Lakes, NJ) and allowed to differentiate for 6-7 days in
medium supplemented with 100 ng/mL nerve growth factor
(Harlan Biosciences).
2.3 PC12 Interactions with F-Ab Derivatives
PC12 cells were equilibrated with 37uC HBSS (Hanks balanced
salt solution) for 30 minutes prior to the start of an experiment.
After equilibration, cells were incubated with a freshly prepared
20 mM F-Ab solution in HBSS containing 10 mM AlexFluor-633
transferrin for 20 minutes. Cells were removed from each well with
either non-enzymatic cell dissociation medium or trypsin. Each
sample was centrifuged at 10006g for 5 minutes and resuspended
in PBS. Unfixed cells were analyzed on a FACSCalibur (Becton-
Dickinson, San Jose, CA) flow cytometer. Argon ion laser light
(l=488 nm) was used to excite fluorescein, and emission
fluorescence was detected with a 585621-nm filter. Helium neon
laser light (l=635 nm) was used to excite the Alexafluor-633
transferrin, and emission fluorescence was detected by 647 nm.
Forward-angle scatter, side scatter, and geometric mean fluores-
cent intensities were recorded from 20,000 cells and analyzed
using Cell Quest (Becton-Dickinson) and WinMDI software. Only
cells were analyzed above a forward-angle scatter threshold that
distinguishes healthy cells. The time from the initiation of
Ab Neuronal Binding in AD
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less than 30 minutes which was well below the time required for
fibril formation; hence, these studies were restricted to monomeric
Ab. The geometric means and the coefficients of variance were
determined using WinMDI version 2.8 software. Statistical
significance between geometric means was determined by the
Mann-Whitney Rank Sum Test using GraphPad InStat software.
2.4 Brain Slice Binding of F-Ab40 and F-Ab H13,14G
Wild-type (WT; B6/SJL strain) mice at 4 months of age were
used in procedures approved by the Mayo Clinic Institutional
Animal Care and Use Committee in strict accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals and. All mice were sacrificed with Nembutal
(200 mg/kg; Ovation Pharmaceuticals, Inc., Deerfield, IL) and
immediately perfused via the aorta with 12ml of 4uC Krebs-Ringer
Bicarbonate Buffer (KRB) pH=7.3 (Sigma-Aldrich, St. Louis,
MO). The animals were decapitated and their brains were carefully
removed from the cranial cavity. Brains were embedded in 2% agar
and cut coronally, by Vibratome (Lancer, St. Louis, MO) into
500 mm-thick slices. Agar was removed; tissue slices containing
cortex and hippocampus were cut into hemisections and placed in
oxygenated (95% O2/5% CO2) KRB at 4uC. Following equilibra-
tioninKRB,eachbrainslicewasincubatedforfiveminutesatroom
temperature in either KRB alone, KRB containing FITC (50 mg/
ml) or KRB containing fluorescein-labeled peptide (F-Ab40 or F-
Ab40 H13,14G; 50 mg/ml; all freshly prepared). Brain slices were
acid stripped to remove extracellular peptides in a 4uC acidified
KRB (pH=5.0) containing no peptide for 5 minutes. Tissue slices
were briefly washed four times in KRB (pH=7.3), mounted on a
coverslip (ThermoFisher Scientific, Inc., Waltham, MA) and
imaged with constant gain using a Zeiss LSM 510 laser confocal
microscope (excitation=488 nm; emission=520 nm, Carl Zeiss,
Inc.,Thornwood,NY).Theimageswereanalyzed usingAxioVision
digital imaging software (Carl Zeiss, Inc., Thornwood, NY). The
mean intensity of all fluorescent cells in the images for each brain
region for each peptide was quantified in an unbiased manner using
a semi-automated image analysis macro. Statistical analysis of F-
Ab40 and F-Ab40 H13,14G mean intensities in the cortex and
hippocampus of 4 month old WT mice was performed by two-way
ANOVA using GraphPad Prism 4 software (GraphPad Software,
Inc., La Jolla, CA).
2.5 Thioflavin-T Solution
ThT was prepared as described by Khurana et al. [32]. Briefly,
approximately 3 mg of ThT (Fluka) was dissolved in 1 mL water.
This solution was further diluted in PBS and filtered through a
0.22-mm syringe filter (Millipore). The concentration of this stock
solution was measured at 416 nm (extinction coefficient: 26,620
M
-1 cm
-1). The solution was stored at 4uC covered in foil and used
up to one week to make assay solutions.
2.6 Fluorescence Assay for Fibril Formation
The fluorescence excitation spectrum of ThT shifts from 340 to
450 when interacting with b-sheet structures. Fluorescence signals
(excitation, 430 nm; emission, 485 nm) reflected the amount of
amyloid fibrils formed. Peptides were dissolved in nanopure H2O
and briefly sonicated (two 10-sec pulses) before PBS was added to
bring the concentration to 200 mM. Peptides were filtered through
0.22-mm syringe filters (Millipore). Aliquots of each peptide were
added to ThT and PBS to give a final peptide concentration of
20 mM and 5 mM ThT in each well of a 384-well plate (Corning).
The plate was incubated at 37uC for three days in a GENios plate
reader (Tecan, Maennedorf, Switzerland), with a three minute
shaking period and fluorescence reading every 20 minutes. The
formation of fibrils was assessed by the maximum fluorescence
signal at the end of 2.5 days and the presence of fibrils was
confirmed by TEM.
2.7 Fibril Formation Kinetics of Ab40 Derivatives
The ThT fluorescence signal of various Ab40 derivatives against
time was fitted to a kinetic model that is routinely used to analyze
protein aggregation kinetic data (Morris et al.). The model is based
on the Finke-Watzky 2-step mechanism. The first step assumes
slow continuous nucleation followed by a second step of fast
autocatalytic surface growth.
k1
A { { { ? { B1 st step

k2
AzB { { { ? { 2B 2nd step

This model suggests that the fibril formation is initiated by the
aggregation of monomers (A) to form nuclei (B) at the rate of k1.
These aggregates are extended by the addition of monomers to
form large fibrils (2B) at the rate of k2. The nonlinear curve fitting
was achieved using WinNonlin
H Professional, version 5.2 (Phar-
sight, Mountain View, CA). Parameters such as the rate constants
k1 and k2, and the amount of 2B formed were estimated for each
Ab40 derivative.
2.8 TEM
Carbon-coated Formvar 300 mesh grids (Electron Microscopy
Sciences) were spotted with 3 mL of sample taken from the 384-
well plate immediately after the fibril formation experiment was
stopped. The negative stain was performed using 2% uranyl
acetate. The grids were stained for 5 minutes and rinsed with
nanopure H2O three times. The samples were observed using a
transmission electron microscope (JEOL Ltd., Tokyo, Japan).
2.9 Surface Plasmon Resonance
Surface Plasmon Resonance (SPR) analyses were performed at
25
oC using Biacore 3000 optical biosensors with research grade
CM5 chips (Biacore, Uppsala, Sweden). Ab40 fibrils were grown
in PBS buffer pH 7.4 at 37
oC under constant shaking at 250 rpm
for 48 hrs. The fibrils were sonicated in a bath sonicator for 3 min,
reconstituted in 10 mM sodium acetate pH 4.0, and about 80 RU
(Relative Units) of Ab40 fibrils were immobilized using carbodii-
mide chemistry to the CM5 chip surface. The binding sensograms
were recorded following the injection of freshly prepared peptides
over the immobilized surface for 5 min at a flow rate of 30 ml/min.
The dissociation profile was monitored for about 15 min, and then
the surface was regenerated with two short 8 sec injections of 50
mM NaOH. Extensive validation studies were performed to
ensure that Ab fibrils immobilized on the chip retained their
binding characteristics even after the regeneration procedure.
Kinetic data analysis was performed using Biaevaluation software
(Version 3.2) provided by Biacore Inc., Uppsala, Sweden.
2.10 Labeling of Amyloid Plaques in APP, PS1 Mouse
Brain Sections In Vitro with Radioiodinated Ab40, Ab40
H13G, Ab40 H13R, or Ab40 H13,14G
HPLC-purified
125I-Ab40,
125I-Ab40 H13G,
125I-Ab40 H13R,
125I-Ab40 H13,14G or buffer was incubated in vitro with unfixed
Ab Neuronal Binding in AD
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transgenic mouse using the same procedure used previously [33].
The rodent Ab was not evaluated because the peptide lacks a
tyrosine amino acid for radioiodination. Briefly, the sections were
incubated for 3 hrs with 100 pM radioiodinated peptide or alone
in 250 ml of TBS (50 mM Tris HCl, 138 mM sodium chloride,
pH 7.0) containing 0.1% BSA, 0.6 mg/ml magnesium chloride,
0.04 mg/ml bacitracin, 0.002 mg/ml chymostatin, and 0.004 mg/
ml leupeptin. After rinsing and air drying overnight at 4uC., the
sections were fixed in formalin for 5 min and then underwent
immunoperoxidase histochemistry (IH) for amyloid using an anti-
Ab monoclonal mouse antibody (4G8, 1:1000, Signet Laborato-
ries, Dedham, MA). Next, the sections were dipped in an
autoradiographic emulsion (Type NTB-3, Kodak, Rochester,
NY) for direct comparison of
125I-peptide labeling to anti-Ab
IH. The slides were dipped in emulsion, exposed for various
durations, and developed according to the instructions. The
sections were dehydrated with successive changes of ethanol and
xylene and then coverslipped.
Results
3.1 Binding of F-Ab40 and F-Ab40H13,14G to PC12 Cells
Rat pheochromocytoma (PC12) cells were differentiated with
nerve growth factor-containing medium and used as a neuronal
cell culture model to assess the binding of of fluorescein-labeled
Ab40 (F-Ab40) and Ab40 H13,14G (F-Ab40 H13,14G). Shifts in
histograms of cellular fluorescence obtained by flow cytometry
analysis indicated mostly membrane-association and/or cellular
uptake of F-Ab with differentiated PC12 cells (Figure 1A). In
addition to being incubated with F-Ab, transferrin conjugated to
AlexaFluor-633 was included as a marker of endocytosis and
healthy, viable cells (data not shown) [34]. Comparison of the
geometric means of these histograms revealed significant differ-
ences in the ability of F-Ab40 and F-Ab40H13,14G to bind to
PC12 cells (Figure 1B). Unlabeled cells show the level of
background autofluorescence. Cells treated with non-enzymatic
cell dissociation medium display cellular fluorescence from both
internalized and membrane-associated peptide. Treatment of cells
with trypsin removes the membrane-associated peptide and
represents F-Ab internalization only. Trypsin-treatment decreases
the fluorescence in cells treated with F-Ab and F-Ab40H13,14G to
the background levels, indicating that the cellular internalization
of these proteins is insignificant at the shorter incubation times
used in this study. Modification of the H13,14 domain significantly
decreases cellular binding compared to native Ab40 (Figure 1B,
black bars). Following the trypsin treatment, the fluorescence in
cells incubated with either peptide returned to background levels
observed in untreated cells (Figure 1B, white bars). The cells
treated F-Ab40 H13,14G did not show any significant difference
before and after trypsin treatment.
3.2 Neuronal Interaction with Ab Derivatives in Brain
Slices
Brain slices from 4 month old WT mice were incubated with F-
Ab40 or F-Ab40 H13,14G to assess cellular interaction (Figure 2).
The binding of the Ab peptides appeared to be selective for
cortical neurons based on the pyramidal morphology of the
fluorescent cells. A comparison of mean fluorescent intensity of
cortical neurons in these WT mice show a significant decrease
(p,0.01) in F-Ab40 H13,14G binding when compared to F-Ab40
(Figure 2A, B, and E). Following F-Ab40 incubation, cortical
neurons had a mean fluorescence intensity of 141634 (mean 6
SD), whereas brain slices incubated with F-Ab40 H13,14G had a
mean fluorescence intensity of 5066 which represents a 65%
decrease in binding. To verify neuronal binding, the hippocampus
was also evaluated. F-Ab40 binding in the hippocampus was
observed only in the pyramidal cells of the stratum pyamidale. The
distinct apical dendrites of the CA1 pyramidal cells are also
fluorescent and can be observed in Fig. 2C as long parallel fibers
projecting from the cell bodies in the lower right of the
micrograph. Although we did not perform any neuron-specific
staining ourselves, the pattern of fluorescence we observed in the
CA1 hippocampal subfield matches the neuron-specific immuno-
histochemical staining as observed by Miya et al. [35]. A
significant decrease (p,0.05) in F-Ab40 H13,14G binding by
hippocampal neurons when compared to F-Ab40 was also
observed (Figure 2C, D and E). Hippocampal neurons following
F-Ab40 incubation had a mean fluorescence intensity of 92622,
whereas brain slices incubated with F-Ab40 H13,14G had a mean
fluorescence intensity of 4466 which represents a 52% decrease in
Figure 1. Binding of F-Ab40 and F-Ab40H13,14G to PC12 cells
as quantified flow cytometry. PC12 cells were incubated with
fluorescein-labeled Ab peptides and cells were harvested using either
trypsin or non-enzymatic cell dissociation medium. (A) Histograms of
cellular fluorescence obtained from flow cytometry analysis. (B)
Geometric means averaged from at least 8 experiments were found
to be significantly different where indicated, as determined by one-way
ANOVA (p,0.0001). ***p,0.001=Untreated cells versus the cells
treated with F-Ab40H13,14G;
+++p,0.001=The cells treated with F-
Ab40 versus the cells treated with F-Ab40H13,14G;
NNp,0.01=F-Ab40
treated cells harvested by non-enzymatic dissociation versus the cells
harvested by trypsinization.
doi:10.1371/journal.pone.0008813.g001
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three times with the same results. These data suggest modifying F-
Ab40 to F-Ab40 H13,14G by substituting glycine for histidine at
domains 13 and 14 significantly decreases neuronal binding in the
cortex and hippocampus.
3.3 Fibril Formation of Ab Peptides
The fibril formation kinetics of the Ab40 derivatives were
determined based on the changes in ThT fluorescence intensity
with time. The modification of the Ab40 histidine 13 to arginine
(H13R) slightly increased the fibril formation rate relative to Ab40
while modification of histidine 13 to glycine (H13G) substantially
increased the fibril formation rate (Figure 3A). However, it is
interesting to note that the lag time with H13G modification
increased remarkably compared to the lag time with the H13R
modification (Table 1A). More strikingly, modifying the entire
histidine 13,14 domain to glycine dramatically enhanced the rate
of fibril formation, which is again associated with a significant
increase in the lag time. The rodent form of Ab (Ab40 R5G,
Y10F, H13R) did not exhibit significant differences in the rate of
fibril formation compared to the human Ab40, yet the lag time
was greater for the rodent form (Table 1A). Due to the unusual
increases in the lag time associated with increases in the rates of
fibril formation, the kinetics were studied in greater detail by fitting
the data to a model that was developed to describe the aggregation
of neurological proteins [36] (Figure 3B). This model is based on
the Finke-Watzky mechanism of nucleation, described by the rate
constant k1, followed by autocatalytic surface growth, described by
the rate constant k2.
The rate constants estimated by the model were highly
significant based on the student t-test. The rate of nucleation of
Ab40H13R and the rodent Ab40 are substantially lower (,1000
fold) than that of human Ab40; whereas, the rate of surface growth
is significantly greater for these Ab derivatives than human Ab40
(Table 1B). The rate constants k1 and k2 obtained by fitting
aggregation model to H13G fibril formation data were about 1/
10
th and 2/3
rd, respectively of the rate constants for native human
Ab40. But the ThT fluorescence intensity was significantly greater
than that of native human Ab40 (Table 1B). These trends became
even more pronounced with the H13,14G modifications. More-
over, the aggregation model did not fit the Ab40H13,14G data as
well as it did the other proteins, which suggests the possibility that
Ab40 proteins with H13G and/or H14G modifications likely
follow a mechanism different from Finke-Watzky mechanism of
nucleation and autocatalytic surface growth. The presence of
fibrils associated with these interesting kinetic trends was
confirmed by TEM (Figure 3C).
3.4 Surface Plasmon Resonance Analysis of Ab
Derivatives to Immobilized Ab40 Fibrils
The binding of various Ab derivatives to immobilized Ab40
fibrils was studied using SPR technique. Freshly prepared
monomeric peptides were injected at a concentration of 75 mM
across an immobilized Ab40 fibril surface. Prior concentration
studies found that 75 mM concentration provided optimized
sensograms for all proteins. Figure 4A shows specific binding of
various Ab peptide derivatives to Ab40 fibrils. The peptides
modified at the histidine positions showed nearly a two fold
enhanced binding response compared to that of native human
Ab40 or rodent Ab40 (Ab40 R5G, Y10F, H13R) (Figure 4B). The
kinetic parameters shown in the Table 2 were obtained by fitting
the association and dissociation phases simultaneously to a
Langmuir model provided with the Biaevaluation software. The
goodness of fit was confirmed based on the low chi-square (x
2)
error values and visual examination of the residual error
distribution. The kinetic parameter values provided in Table 2
were determined to be highly significant using Student’s t-test.
The association rate constant (ka) of various Ab derivatives
binding to fibrillar Ab40 varied between 31 to 55 M
-1s
-1.A b40
exhibited the maximum ka value of 55 M
-1s
-1 followed by
Ab40H13G, Ab40H13,14G, Ab40H13R, and the rodent Ab40
R5G, Y10F, H13R. Statistically significant differences were also
observed between the dissociation rate constants (kd) of various
peptides from the fibrillar Ab40. Ab40H13,14G demonstrated the
Figure 2. In vitro binding of F-Ab40 and F-Ab40 H13,14G in
neurons of 4 month old WT brain slices. (A) Cortex incubated with
F-Ab40. (B) Cortex incubated with F-Ab40 H13,14G. (C) Hippocampus
incubated with F-Ab40 (D) Hippocampus incubated with F-Ab40
H13,14G. Scale bar equals 50 mm. (E) Mean fluorescent intensity of
cortical and hippocampal neurons from brain slices incubated with F-
Ab40 or F-Ab40 H13,14G. Analysis of Variance (ANOVA) [F(1,8)=33.73;
p,0.001] followed by Bonferroni post-hoc multiple comparisons:
Cortex - **p,0.01; Hippocampus - *p,0.05.
doi:10.1371/journal.pone.0008813.g002
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PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8813Figure 3. Fibril formation of Ab derivatives. (A) Thioflavin T signal versus time of amyloid b peptides. Peptide samples, at 20 mM and containing
thioflavin T, were excited at 430 nm and the emissions at 485 nm were monitored over 2.5 days at 37uC with periodic shaking. For each peptide,
n=18. (B) Thio-T fluorescence representing the fibril formation kinetics of various Ab40 derivatives fitted to the Finke-Watzsky 2-step aggregation
model [36]. The observed data has been indicated by various symbols. The predicted data obtained through curve-fitting is presented as solid lines.
(C) TEM confirmation of the presence of amyloid fibrils formed by the corresponding amyloid b peptide described in panel A (a: Ab40 H13,14G; b:
Ab40 H13G; c: Ab40; d: Ab40 H13R; e: Ab40 R5G, Y10F, H13R). The sample was collected at the end of the fibril formation experiment and applied to a
grid and negatively stained with uranyl acetate. Scale bar equals 1 mm.
doi:10.1371/journal.pone.0008813.g003
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Ab40H13R, and the rodent Ab40 R5G, Y10F, H13R. The
equilibrium binding constant (KD), which has an inverse
relationship to the affinity of various peptides to the Ab40 fibrils,
was the highest for rodent Ab40 R5G, Y10F, H13R followed by
Ab40H13R, Ab40, Ab40H13G, and Ab40 H13, 14G. These
results demonstrate that Ab40H13, 14G has a higher affinity to
Ab40 fibrils with low equilibrium dissociation constant of 1.2 mM
compared to the rest of the peptides (Figure 4).
The results from SPR studies demonstrate that whether Ab40 is
in a monomeric or randomly oriented structure, removal of the
imidazole side chain from histidine at position 13 and 14 results in
increased affinity when it interacts with the b-sheet Ab40 fibrils.
This histidine substitution results in a strong interaction with
fibrillar Ab40 and takes more time to dissociate from the fibrillar
surface. The histidine modification at positions 13 and 14 of Ab40,
therefore, increases its avidity to fibrillar Ab40.
3.5 Labeling of Amyloid Plaques in APP, PS1 Mouse Brain
Sections In Vitro with Radioiodinated Ab40, Ab40 H13G,
Ab40 H13R, or Ab40 H13,14G
HPLC-purified
125I-Ab40,
125I-Ab40 H13G,
125I-Ab40 H13R,
and
125I-Ab40 H13,14G were incubated in vitro with unfixed
cryosections of brain from a 20-month old APP, PS1 AD
transgenic mouse. The results are illustrated in Figure 5, which
displays micrographs of typical binding in mouse cortex for each
peptide. All four peptides labeled amyloid plaques equally well,
and in all regions of mouse brain, exposing many silver grains after
only one day of exposure. These binding studies were performed
twice in mouse brain sections and once in human AD brain
sections with the same results. With equal counts or amounts of
peptide, all four Ab40 peptides labeled plaques with more affinity
than any of the Ab30 derivatives that were tested previously [37].
Discussion
These data suggest that the mechanism of neuronal binding of
Ab in Alzheimer’s disease involves the adjacent histidine residues
of Ab which facilitates a biophysical interaction with neuronal cell
surface lipids and proteins that results in its accumulation in
healthy neuronal cell bodies and dendrites (Figure 6). It is likely
that the intraneuronal Ab forms fibrils, which ultimately affects a
variety of functions within the neurons characterized by alterations
in synaptic function and the onset of dementia. These damaged
neurons eventually die and lead to the production of neuritic
plaques which are characterized by accumulation of Ab fibrils,
dystrophic neurites, reactive gliosis (astrocytes), extracellular
filaments, and activated microglial, as well as a host of other
proteins that have been found associated with these neuritic
plaques. We hypothesize that this is a destructive pathway that
occurs over a long period of time (perhaps decades) in Alzheimer’s
disease. In contrast, a large amount of Ab that is produced forms
soluble monomers, dimers, and oligomers and ultimately insoluble
protofibrils and fibrils that result in the Ab deposition as diffuse/
compact/dense core plaques. We suggest that this is a protective
mechanism for removing excessive production of Ab. Interesting-
ly, those Ab deposits that are found in brains of pathological aging
individuals without clinical symptoms of cognitive deficits are
exclusively diffuse amyloid plaques and support this proposed
protective mechanism for removing excess levels of Ab.
Several mechanisms have been proposed to describe the
interactions of soluble Ab proteins with neurons which ultimately
cause neurodegeneration. In a recent report, Simakova and Arispe
[38] have shown that Ab proteins elicit their toxicity by binding to
the neuronal cell membrane. On the other hand, numerous
reports have claimed that Ab proteins are internalized by neurons
via receptor mediated endocytosis, escape degradation in lyso-
somes, and accumulate in the cytosol [39-41]. We have recently
proposed a radically different mechanism that Ab proteins are
internalized by neurons via non-endocytotic and energy indepen-
dent pathways, most likely due to their ability to biophysically
interact with the neuronal membrane [13]. Consequently, a
significant amount of the internalized protein accumulates outside
of the endosomal or lysosomal compartments in the neuroplasm
without degradation. Whether the neurons are distressed by mere
binding of Ab proteins to the neuronal membrane or by
Table 1. Fibril Formation Kinetics of Ab40 Derivatives.
A) Lag time and slope obtained from thioflavin T fluorescence graphs
Peptide Lag time, hrs Slope, RU/hr
Ab40 H13,14G 4.92 3501680.6
Ab40H13R 1.10 911621.0
Ab40 H13G 3.70 1507627.3
Ab40 0.88 53965.0
Ab40 R5G, Y10F, H13R 2.97 67669.6
B) Kinetic parameters obtained by fitting experimental data to the protein aggregation model. [36]
Mutant k1 (x10
3), hr
-1 k2 (x10
3), hr
-1 Max. fluorescence intensity (R.U.)
Ab40 H13,14G 2.72662.7 0.02860.001 234386332
Ab40 H13R 0.00160.0008 0.21860.038 37136263
Ab40 H13G 9.367.6 0.04160.002 122926210
Ab40 79.3614.1 0.06660.007 41436110
Ab40 R5G, Y10F, H13R 0.000160.0001 0.21960.012 3397655
k1: rate of nucleation.
k2: rate of fibril growth.
doi:10.1371/journal.pone.0008813.t001
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eventually lead to synaptic loss and neurodegeneration needs
further resolution. Nevertheless, both situations are impacted by
the ability of Ab proteins to bind to the neuronal membrane. It
would be important to further assess neuronal binding of Ab42 as
well as oligomers of Ab. The assessment of oligomeric binding
might be more problematic as the fluorescein derivative is added
to Ab during its synthesis which might affect subsequent formation
of oligomers.
Recent studies have investigated Ab-cell membrane interactions
which were found to be inhibited by annexin V, a specific ligand
for phosphatidylserine [42,43]. Membrane binding of Ab that is
required for its cell-selective neurotoxicity was also shown to be
determined by surface phosphatidylserine [38]. It was recently
shown that annexin V inhibited L-Ab42 but not D-Ab42 binding
to cultured cortical neurons yet rescued L-Ab42 neurotoxicity
[44], thus emphasizing the importance of phosphatidylserine in
the biophysical binding of Ab to neurons.
The current study provides critical information on the amino
acids that enable Ab peptide to anchor to the neuronal membrane.
The experiments reported in this study demonstrated that
substitutions of the adjacent histidines residues of fluoroscein-
labeled Ab40 (F-Ab) with glycine decreased binding/uptake in
differentiated PC12 cells by approximately 60% as assessed by
flow cytometry analysis (Figure 1). However, no significant
differences were observed in cells treated with trypsin, which
removed most of the peptides bound to the cell surface. More
interestingly, there was no difference in F-Ab40 H13,14G
fluorescence before and after trypsin treament suggesting that it’s
binding to PC12 cells is very modest. It is obvious from this data
that F-Ab40 has higher binding to PC12 cells than F-Ab40
H13,14G. The shorter incubation times (20 min) used for these
studies are appropriate to reach conclusions on the binding, but
they are very short to draw conclusions on the cellular uptake
behavior. Studies have to be conducted with longer incubation
times to compare the extent of internalization of these peptides in
neuronal cells. To more accurately reflect the situation in normal
brain, the binding of these peptides to adult neurons was also
determined in a mouse brain slice model. The H13,14G
substitutions on F-Ab40 substantially reduced binding to cortical
neurons by 65% and to hippocampal neurons by 52% in WT
brain slices compared to F-Ab40 (Figure 2). Clearly, the adjacent
histidine residues on Ab40 play an important role in at least some
of the binding of Ab40 to the neuronal surface and probably for its
internalization as well.
These adjacent histidine substitutions on Ab40 also enhanced
fibril formation as evaluated by ThT binding (Figure 3) and
increased binding to Ab fibrils as demonstrated by surface
plasmon resonance (Figure 4), with a sustained ability to bind to
amyloid plaques (Figure 5). Substitution of the histidine residues,
therefore, is hypothesized to drive Ab along a protective pathway
that will ultimately result in the increased accumulation of diffuse/
compact/dense core plaques (modeled in Figure 6). Substitution of
these histidine residues or agents that would mask these histidine
residues may have therapeutic potential for preventing neuronal
uptake and subsequent accumulation in neurons and ultimately
the destruction of the neuron and drive the protein to the
protective pathway involving diffuse/compact/dense core plaque
accumulation.
Because of the presumed protective role of diffuse/compact/
dense core plaques, which are formed from the nuclei of Ab fibrils,
the propensity of various Ab derivatives to form fibrils was
investigated. The kinetics of fibril formation was primarily
followed using a ThT-binding assay (Figure 3). The H13R
modification, which substitutes positively charged histidine with
arginine of the same charge on Ab40, increased the rate of fibril
Figure 4. Substitution of the histidine residues of Ab increases
its avidity to human Ab40 fibrils compared to the native or
rodent Ab as demonstrated by surface plasmon resonance. (A)
Freshly prepared Ab40 derivatives (75 mM) were injected over
immobilized Ab40 fibrils at a flow rate of 30 ml/min for 5 min and the
dissociation monitored for 15 min. Reference subtracted sensograms
are overlayed. (B) Bar chart shows the difference in relative response
units of different Ab derivatives binding to Ab40 fibrils at the end of
injection time (Time=525 sec).
doi:10.1371/journal.pone.0008813.g004
Table 2. Kinetic Rate Constants of Ab40 Derivatives Binding
to Immobilized Ab40 Fibrils Determined by Surface Plasmon
Resonance.
Peptide
ka (M
-1s
-1)
610
2
kd (s
-1)
610
-4
KD (M)
610
-6 x
2
Ab40 H13, 14G 0.45 0.5 1.2 0.75
Ab40 H13R 0.39 2.9 7.5 1.25
Ab40 H13G 0.51 1.3 2.5 4.35
Ab40 0.55 1.6 2.9 0.99
Ab40 R5G, Y10F, H13R 0.31 3.3 10.8 1.47
doi:10.1371/journal.pone.0008813.t002
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H13R modification along with two other modifications (R5G, and
Y10F), also demonstrated similar fibril formation kinetics.
However, when the histidine at position 13 was substituted with
an amino acid carrying no charge at physiological pH, such as
glycine, the rate of fibril formation increased significantly;
however, the lag time also increased. Substituting histidines at
both positions 13 and 14 with glycine enhanced the rate of fibril
formation further and also extended the lag time significantly.
To analyze these interesting trends further, the kinetic data was
fitted to a model that describes Finke-Watzsky mechanisms of
nucleation followed by autocatalytic surface growth. The curve
fitting results outlined in Table 1 demonstrated that the nucleation
rate of Ab40 was much greater than any of the derivatives.
However, the nucleation rate (k1) decreased drastically (1/10000
to 1/1000000) followed by a modest 3-fold increase in the rate of
fibril growth (k2) for the peptides with H13R substitution (Ab40
H13R and rodent Ab40), which was most likely responsible for the
observed lag times. In the case of H13 substitution to glycine, the
rate constants k1 and k2 decreased to 1/9 and 2/3 compared to
that of native Ab40. These changes in k1 and k2 can explain the
prolongation of lag time with Ab40 H13G compared to Ab40, but
fall short of explaining why this substitution forms more fibrils than
the native Ab40. The magnitude of these kinetic trends increases
remarkably with the substitutions of both adjacent histidines at
positions 13 and 14 with glycines, suggesting that the fibril
formation kinetics of Ab40 H13G and Ab40 H13,14G deviate
from the classical Finke-Watzsky mechanism. This view point is
also supported by the observation that the model did not fit the
nucleation and fibril growth phases of Ab40 H13G and Ab40
H13,14G as well as it did with the other derivatives. Although the
Finke-Watzsky model is the simplest model capable of describing
various factors that characterize nucleated aggregation of various
neurological proteins, including Ab40, this phenomenological
model may be inadequate, (also acknowledged by Morris et. al
[36]), in describing the events of a complex multistep aggregation
process. More detailed biophysical studies are being conducted in
our lab to study the unique aggregation mechanism of the Ab40
H13G and Ab40 H13,14G peptides.
The AD brain is expected to contain a significant amount of
pre-existing Ab fibrils and diffuse plaques. The Ab40 derivatives
are expected to bind to these amyloid forms, thus making them
unavailable for neuronal interactions. Therefore, the ability of
Ab40 derivatives to bind to preformed Ab fibrils and to amyloid
plaques in the APP, PS1 mouse brain sections was determined
using surface plasmon resonance (SPR) and emulsion autoradiog-
raphy techniques, respectively. The SPR studies demonstrated
that Ab40 H13,14G maintains the highest binding to preformed
Ab fibrils (Figure 4). Moreover, this derivative also exhibited
similar binding to amyloid plaques in the AD mouse brain as Ab40
(Figure 5). Hence, masking of these histidine residues may drive
Ab toward protective plaque formation rather than neuronal
binding and accumulation.
In summary, these experiments indicate that the HH domain of
Ab provides at least in part the structural basis for its neuronal
binding.
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